On March 2, 2023 Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, reported that Biomea’s management is scheduled to host investor meetings and participate in the following upcoming events (Press release, Biomea Fusion, MAR 2, 2023, View Source [SID1234628051]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A virtual fireside chat with Oppenheimer & Co.: Type 2 Diabetes and New Treatment Options with Biomea Fusion (BMEA) Mgmt. & Key Opinion Leaders on Thursday, March 2nd at 12:00 PM (EST)
Barclays Global Healthcare Conference in Miami:
A fireside chat on Tuesday, March 14th at 4:35 PM (EST)
1×1 Meetings: Tuesday, March 14th, 2023
Oppenheimer’s 33rd Annual Healthcare Conference:
A virtual fireside chat on Wednesday, March 15th at 11:20 AM (EST)
1×1 Virtual Meetings: Monday, March 13th, 2023
A webcast of the fireside chats will be available on the investor page of Biomea’s website at View Source, with archived replays available following the events.